Dolutegravir/abacavir/lamivudine: Considerable added benefit for some adults with HIV

9 enero 2015

Upon evaluating the new fixed-dose combination of dolutegravir/abacavir/lamivudine for adolescents and pretreated adults with HIV, added benefit is not proven because suitable data are lacking. However, there is an indication that adults who have not been treated for their HIV infection have considerable added benefit from treatment with the new fixed-dose combination.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/EvDty6fGpg4/150109093723.htm

Volver